TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Is There an Interest in Repeating the Vaginal Administration of Dinoprostone (Propess®), to Promote Induction of Labor of Pregnant Women at Term?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient who is \>=18 years.~* Term pregnancy \> 37 weeks~* Induction of labor in progress, medically indicated~* Patients who have had the establishment of a first Propess®, within 24 to 36 hours (before signing the consent)~* Cephalic presentation~* Unfavorable cervical conditions (Bishop score \<6) 1 hour prior to inclusion~* Intact Membranes~* Affiliated with a social security system~* Having signed the consent form.~Exclusion Criteria:~* Multiple pregnancy~* Uterus scar~* Contraindications to epidural anesthesia~* Contraindications to Propess®: recent history of pelvic inflammatory disease; hypersensitivity to prostaglandins Adverse effects appeared in the first Propess®: anaphylactic shock, disseminated intravascular coagulation (DIC).~* Contraindications to Syntocinon: Hypersensitivity to oxytocin, cardiovascular disorders and severe toxemia of pregnancy.~* Contraindications to vaginal delivery (placenta previa, previa obstacle ...)~* Premature Rupture of Membranes (PROM)~* Intra Uterine Growth Retardation (IUGR) \<3rd percentile~* Macrosomia\> 97th percentile~* Severe Impaired fetal heart rate~* In Utero Fetal Death (IUFD)~* Medical Termination of pregnancy or lethal fetal pathology~* Patient under guardianship or trusteeship safeguard justice

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dinoprostone (Type: EXPERIMENTAL): In case of failure of cervical ripening after a first intravaginal delivery device of Dinoprostone (Propess® 10 mg), patients receive a second Propess®, followed by Oxytocin 5U.I/ml (Syntocinon®) (if necessary) and epidural analgesia if desired by the patient.
- Oxytocine (Type: ACTIVE_COMPARATOR): In case of failure of cervical ripening after a first intravaginal delivery device of Dinoprostone (Propess® 10mg), patients receive directly Oxytocin 5U.I/ml (Syntocinon®) and epidural analgesia if desired by the patient.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Customizing First Line Chemotherapy in Advanced Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Microscopic diagnosis of NSCLC stages IIIB (with malignant pleural effusion) and IV~2. Having adequate tissue sample to perform the markers testing~3. Age ≥ 18 years~4. No prior chemotherapy treatment for lung cancer (Surgery and radiotherapy are acceptable)~5. No other concurrent cancer treatment~6. Performance status of 0- 2 per ECOG scale (Appendix II)~7. Adequate laboratory values as follows as follows:~   Absolute neutrophil count ≥ 1500/mm3 Platelet count ≥100, 000/ mm3 Total bilirubin ≤ 1.25X institutional upper normal level AST and ALT ≤ 3 X institutional upper normal level Serum creatinine ≤ 1.5 X institutional upper normal level~8. Presence of measurable disease~Exclusion Criteria:~1. Prior systemic treatment for lung cancer~2. History of hypersensitivity to drugs used~3. Diagnosis of other malignancy in the last 5 years excluding curatively treated non-melanoma skin cancer and in-situ cervical cancer~4. Medical illness that puts the patient at significant risk per investigator's discretion~5. Uncontrolled CNS disease. Patients with CNS metastatic disease treated with radiotherapy or surgery will be eligible if the CNS disease is stable 4 weeks after the treatment initiation without increase dose of steroids~6. Positive pregnancy test or refusal to use contraception during treatment. (Gynecology consultant for contraception)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cisplatin,Docetaxel,Gemzar, Premetrexed (Type: EXPERIMENTAL): Patients will receive treatment for up to six cycles of the assigned regimen unless there is disease progression or unacceptable toxicities. After treatment, the patients will be seen every 2 months for the first year, then every 3 months for the second year and every 6 months afterwards.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Placebo Controlled, Randomized, Double Blind Trial of Milnacipran for the Treatment of Idiopathic Neuropathy Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients age 18 to 80 years~* Patients with signs and symptoms of a peripheral neuropathy, with either abnormal nerve conductions or abnormal epidermal nerve fiber density with neuropathic pain.~* Pain will have been present for at least 6 months~* Patients may be on other medications for neuropathic pain (eg, antiepileptic medications, opiates or non steroidal antiinflammatories); however they must be on a stable dose for 4 weeks prior to, with no plan to change during the study~* All patients must have had a normal fasting glucose or B12, thyroid stimulating hormone, and serum protein electrophoresis, since the onset of their symptoms.~Exclusion Criteria:~* Other cause of neuropathy (eg, diabetic neuropathy, toxic neuropathy, HIV neuropathy, celiac neuropathy, inherited neuropathy)~* Unstable angina~* Use of another serotonin and norepinephrine reuptake inhibitors (eg, duloxetine, venlafaxine), tricyclic antidepressants, monoamine oxidase inhibitors (MAOI) or selective serotonin reuptake inhibitors~* Myocardial infarction stroke or life threatening arrhythmia within the last 6 months~* HIV infection~* Hepatic or renal failure~* Pregnancy~* narrow angle glaucoma~* History of epilepsy or a seizure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Milnacipran (Type: EXPERIMENTAL): Patients will receive Milnacipran
- Placebo (Type: PLACEBO_COMPARATOR): Patients will receive Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Sulfadoxine-Pyrimethamine for Treating Malaria in Gabonese Children

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male and female outpatients~* Aged 6 to 59 months~* Body weight between 7.5 to 30 kg~* uncomplicated falciparum malaria with parasitaemia between 1,000/µL and 200,000/µL~* Ability to tolerate oral therapy~* Informed consent, oral agreement of the child if appropriate~Exclusion Criteria:~* Still in IPTi trial and/or still in any other intervention trial~* Known G6PD-deficiency~* Presence of severe malnutrition~* Inability to drink or breastfeed~* Recent history of convulsions, lethargy or unconsciousness;~* Signs of severe and complicated~* Mixed/mono infection that includes a non-P. falciparum species.~* Hb \< 7g/dl~* Inability to attend stipulated follow-up visits.~* History of hypersensitivity reactions to the drug being evaluated

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 59 Months
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Open Label Pharmacokinetic in Adult Patients With Ventilator-Associated Pneumonia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Informed Consent~* Between 18 and 75 years of age inclusive~* VAP - 48 hours after onset of mechanical ventilation~* BMI 18 - 35 inclusive~* Albumin \< 3.3 g/dL or clinical evidence of edema~* Negative Pregnancy test~* Expected survival of at least 7 days~Exclusion Criteria:~* Renal impairment (CrCl \< 80 mL/min)~* Known drug allergy (including penicillin, cephalosporin, carbapenems, or other beta-lactams)~* History of seizures~* Sustained shock, unresponsive to sympathomimetics~* Conditions that may have jeopardized adherence to the protocol (NYHA Class 4 cardiac disease, \>15% total body burn or significant third degree burn)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Ceftobiprole (Type: EXPERIMENTAL): Ceftobiprole, 1 G q8h as 4 hour infusions for 2 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ataluren for Nonsense Mutation Methylmalonic Acidemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Major Inclusion Criteria:~* Ability to provide written informed consent (parental/guardian consent if applicable)/assent (if applicable)~* Age ≥2 years~* Phenotypic evidence of methylmalonic acidemia (MMA) based on the presence of characteristic clinical symptoms or signs and an elevated plasma MMacid level (\>0.27 micromole/liter (umol/L)~* Presence of a nonsense mutation in at least 1 allele of the mutase (mut), Cobalamin A (cblA), or Cobalamin B (cblB) gene~* Glomerular filtration rate ≥30 milliliters (mL)/minutes/1.73 meters squared (m\^2), serum aminotransferase values ≤2.5\*the upper limit of normal, serum bilirubin ≤1.5\*the upper limit of normal, plasma adrenocorticotropic (ACTH) within normal limits~* Willingness and ability to comply with scheduled visits, drug administration plan, study restrictions, and study procedures~Major Exclusion Criteria:~* Known hypersensitivity to any of the ingredients or excipients of the study drug~* Any change in chronic treatment for MMA within 2 months prior to start of screening laboratory assessments~* Episode of metabolic decompensation within 1 month prior to start of Screening laboratory assessments~* History of organ transplantation~* Ongoing dialysis for renal dysfunction

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ataluren (Type: EXPERIMENTAL): Cycle 1: Ataluren treatment will be taken 3 times per day with meals for 28 days at doses of 5 mg/kg (morning), 5 mg/kg (midday), and 10 mg/kg (evening); there will then be an interval of 21 up to 42 days without treatment.~Cycle 2: Ataluren treatment will be taken 3 times per day with meals for 28 days at doses of 10 mg/kg (morning), 10 mg/kg (midday), and 20 mg/kg (evening); there will then be an interval of 14 days without treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: F-choline PET in Early Response Assessment for Castration Resistant Prostatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years~* Eastern Cooperative Oncology Group (ECOG)performance status score of 2 or less~* Histologically or cytologically confirmed adenocarcinoma prostate cancer without neuroendocrine component (component with minority neuroendocrine) or small cell, or neuroendocrine cells or small minority component prostate who underwent surgical or medical castration~* Disease progression during or after a docetaxel-based chemotherapy~* serum testosterone level of 50 ng per deciliter or less (≤2.0 nmol per liter)~* Biologic criteria :~* platelets ≥ 100 000/μl,~* Creatinine \<1.5 x upper limit or creatinine clearance ≥ 60 ml / min,~* Serum potassium ≥ 3.5 mmol / l,~* Bilirubin \<1.5 x upper limit of normal (ULN)~* hemoglobin ≥ 9.0 g / dl without any transfusion.~Exclusion Criteria:~* abnormal aminotransferase levels (levels of aspartate aminotransferase or alanine aminotransferase that were ≥2.5 times the upper level of the normal range; patients with known liver metastasis who had levels of aspartate aminotransferase or alanine aminotransferase that were ≤5 times the upper level of the normal range were eligible to participate~* previous therapy with ketoconazole~* serious coexisting nonmalignant disease :~* active or symptomatic viral hepatitis or chronic liver disease,~* uncontrolled hypertension,~* a history of pituitary or adrenal dysfunction,~* clinically significant heart disease

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- F-Choline PET (Type: EXPERIMENTAL): The F-Choline-PET will be performed before and at 6 weeks of the beginning of treatment by abiraterone acetate or enzalutamide.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Controlled Trial of Treatment of Bacterial Vaginosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnant women 18 to ≤50 years with the ability to give informed consent.~* Patients expected to have a vaginal delivery with no obstetric contraindication for vaginal delivery at time of screening.~* Diagnosed with bacterial BV per Amsel criteria at time of screening in clinic.~* Gestational age ≥ 35 weeks~Exclusion Criteria:~* Plan for elective cesarean delivery~* Allergy or contraindications to metronidazole~* Receipt of metronidazole or clindamycin on admission for delivery for other indications.~* Hemodialysis~* Severe liver dysfunction~* Patient reports BV to nurse or clinician provider at current clinic visit or has been treated for BV within the past 3 months.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Metronidazole 500 mg (Type: ACTIVE_COMPARATOR): Participants in this arm will receive metronidazole 500 mg twice daily, orally for 7 days
- Placebo (Type: PLACEBO_COMPARATOR): Participants in this arm will receive placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Image-Guided SBRT for Vertebral Metastases

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18years.~* WHO performance status ≤ 2 (ECOG - KPS).~* Histologically-proven of primary cancer disease.~* Metastatic disease in the spine, from C1 to Sacrum. A maximum number of 5 sites. Each of the separate sites may have a maximal involvement of 2 contiguous vertebral bodies.~* Epidural compression is eligible when there is at least 3 mm gap between the spinal cord and the edge of the epidural lesion, unless patient underwent decompression surgery.~* A paraspinal mass ≤ 5 cm.~* Minimal residual tumor after surgery~* Metastases in other district of the body are allowed.~* Informed consent.~Exclusion Criteria:~* \> 50% loss of vertebral body height.~* Prior radiation to the interested spine.~* Patients for whom an MRI of the spine is medically contraindicated.~* Patients allergic to contrast used in MRIs or CT scans or who cannot be premedicated for the use of contrast.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vertebral metastases (Type: None): Selected patients with spine metastases are treated with ablative single dose SBRT and VMAT technique in various solid tumors .

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of any of the following for at least 4 weeks:~  * Stage IIIB (with effusions) or stage IV non-small cell lung cancer~ * Extensive stage small cell lung cancer~ * Stage III or IV pancreatic cancer~ * Stage IV liver cancer~ * Stage III or IV gallbladder cancer~ * Stage III or IV bile duct cancer~ * Stage IV esophageal cancer~ * Stage IV gastric cancer~ * Second line stage IV colorectal cancer~* Meets diagnostic and Statistical Manual of Mental Disorders-4th Edition and Endicott criteria for major depressive disorder~* Duration of depressive symptoms ≥ 4 weeks~* Hamilton Depression D 17 (HAM-D 17) Scale ≥ 14~* No active suicidality requiring immediate care or psychiatric hospitalization~PATIENT CHARACTERISTICS:~* Able to swallow pills~* No active substance abuse disorder (including alcohol abuse within the past 6 months), psychotic disorder or active psychotic symptoms, organic mental disorders, or bipolar disorder~* No clinical or laboratory evidence of hypothyroidism~* No hypercalcemia~* No severe anemia, defined as hemoglobin \< 10 g/dL~* No history of multiple adverse drug reactions or allergy to study drugs~* Not pregnant~* No history of head trauma~* No history of epilepsy~PRIOR CONCURRENT THERAPY:~* No other concurrent antidepressant medications or psychostimulants

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Placebo-Placebo (Type: PLACEBO_COMPARATOR): Participants in this arm were randomized to receive placebo once daily for the first 4 weeks and placebo once daily for the second 4 weeks
- Placebo-Escitalopram (Type: OTHER): Participants in this arm were randomized to receive placebo once daily for the first 4 weeks and escitalopram oxalate 10 mg once daily for the second 4 weeks
- Escitalopram-Placebo (Type: OTHER): Participants in this arm were randomzied to receive escitalopram 10 mg once daily for the first 4 weeks and placebo once daily for the second 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Drotaverine in Dysmenorrhoea Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* History of at least 6 months of dysmenorrhea, with presence of moderate to severe pain in each of the last 3 cycles~* With regular menstrual cycles (25-35 days)~* Using an adequate barrier contraception method (except for virgins)~Exclusion Criteria:~* Evidence of clinically relevant gynecological, cardiovascular, hematologic, hepatic, gastrointestinal, renal, pulmonary, endocrinologic, neurologic or psychiatric disease, based on a clinical assessment and routine laboratory investigations~* Proven hypersensitivity to drotaverine hydrochloride or ibuprofen or proven intolerance to lactose~* Any described contraindication to either drotaverine hydrochloride or ibuprofen (see Summary of Product Characteristics)~* Oestro-progestative contraception within the last 2 months~* Regular use of sedative, hypnotics, tranquillizers or any other addictive agents~* History or evidence of acute or chronic alcohol abuse~* Heavy smoking (\> 10 cigarettes/day)~* Need of a permanent treatment with other antispasmodics and/or analgesic agents during the trial~* Lactation~* Pregnancy~* Participation in another clinical trial in the last 3 months prior to the start of this study~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- drotaverine + Ibuprofen placebo (Type: EXPERIMENTAL): Drotaverine 80 mg plus ibuprofen placebo orally
- Drotaverine placebo + ibuprofen (Type: ACTIVE_COMPARATOR): Drotaverine placebo plus ibuprofen 400 mg orally
- Drotaverine + ibuprofen (Type: ACTIVE_COMPARATOR): Drotaverine 80 mg plus ibuprofen 400 mg orally

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues